The current financial score of Cellectar Biosciences Inc is 7.19. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Cellectar Biosciences Inc is 6.92. Its current P/E ratio is -0.41, which is -138.27% below the recent high of 0.16 and -92.75% above the recent low of -0.80.
The current earnings forecast score of Cellectar Biosciences Inc is 8.50. The average price target is 11.50, with a high of 15.00 and a low of 10.00.
The current price momentum score of Cellectar Biosciences Inc is 3.63. Currently, the stock price is trading between the resistance level at 2.49 and the support level at 2.07, making it suitable for range-bound swing trading.
The current institutional shareholding score of Cellectar Biosciences Inc is 3.00. The latest institutional shareholding proportion is 6.26%, representing a quarter-over-quarter decrease of 38.18%.
No risk assessment score is currently available for Cellectar Biosciences Inc. The Pharmaceuticals industry's average is 5.56. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.